Relation Therapeutics Ltd bags US$35m in seed financing.
London-based virtual drug discovery specialist Relation Therapeutics Ltd has closed another US$35m seed financing round, bringing its total seed fundraise to US$60m.
Researcher find potential target for atherosclerosis
TREM2, a receptor on the surface of macrophages, reduces necrotic core formation in early atherosclerosis, a German-Austrian reseach team reports.
Obesity: Arecor Therapeutics partners with TRx Biosciences
British companies Arecor Therapeutics plc and TRx Biosciences Ltd combine their technologies to formulate an oral GLP-1 receptor agonist with enhanced bioavailability<br />
Scientist create non-digestible aptamer
German researchers for the first time have expanded the half life of oligonucleotide-based drugs using artificial building blocks that mimic the features of RNA/DNA but are not digestible by enzymes.
Scientists create non-digestible aptamer
German researchers for the first time have expanded the half life of oligonucleotide-based drugs using artificial building blocks that mimic the features of RNA/DNA but are not digestible by enzymes.
SynaptixBio Ltd gets FDA ODD for leukodystrophy
Rare disease specialist SynaptixBio Ltd has got its second FDA orphan drug designation for a subtype of TUBB4A leukodystrophy.
Pierre Fabre SAS in US$31m licence deal with Kinnate Biopharma Inc
Pierre Fabre Médicament SAS has entered into an Asset Purchase Agreement (APA) over pan-RAF programs developed by Kinnate Biopharma Inc.
Bayer SE secures rights to in €310m deal
Bayer AG has purchased European commercialisation rights for the transthyretin amyloid cardiomyopathy candidate acoramidis from BridgeBio Inc.<i> </i>
PulseSight to disrupt AMD space
<span style="mso-ansi-language:EN-GB" lang="EN-GB">PulseSight Therapeutics SAS was launched on Wednesday, backed by seed financing from Pureos Bioventures and ND Capital. The company introduces a disruptive </span><span style="mso-bidi-font-family:Aptos;mso-bidi-theme-font:minor-latin;color:#272727; mso-ansi-language:EN-US" lang="EN-US">delivery platform </span><span […]
Swiss vaccine developer Limma Tech get CARB-X grant
Swiss multivalent vaccine developer LimmaTech Biologics AG has been awarded US$2.2m rom the Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X).